Immuneering Corporation

IMRX • Biotechnology

$3.73

— 0.00 (0.00%)

Precio actual

ResultadosÚltimo reporte: 30 jun 2026

PERFIL DE MAYOR RIESGOPrecauciónConfianza: 70%

Perfil cuantitativo — no constituye una recomendación de inversión.

Perfil cuantitativo — no constituye una recomendación de inversión.Metodología

Tesis del análisis: Conviene actuar con cautela. Los ratios recientes muestran debilidades que pueden limitar el retorno si los fundamentales no mejoran.

Capitalización

$241.25M

Crecimiento

-100.0%

Flujo de caja

0/5

Tendencia

Negative

Evidencia

Nivel de deuda manejable · 0.02Liquidez saludable · 17.5Tendencia de crecimiento negativaRentabilidad débil

Datos financieros hasta: 30 jun 2026, 12:00 a.m. UTCÚltima actualización de earnings: 30 jun 2026, 12:00 a.m. UTCÚltima actualización del perfil: 14 ago 2026, 12:58 p.m. UTC

Resumen de la compañía

Valoración, calidad, fortaleza financiera, momentum y datos de analistas.

Price$3.73

Change0.00%

Shares Out64.68M

Market Cap$241.25M

Enterprise Value$91.35M

52W Range3.00 - 10.08

Beta0.37

P/E-4.21

P/S668.36

P/B1.26

P/FCF-0.01

EV/Sales253.07

Price$3.73

Change0.00%

Shares Out64.68M

Market Cap$241.25M

Enterprise Value$91.35M

52W Range3.00 - 10.08

Beta0.37

P/E-4.21

P/S668.36

P/B1.26

P/FCF-0.01

EV/Sales253.07

EV/EBITDA-1.44

EV/FCF-0.00

Earnings Yield-23.74%

Dividend Yield0.00%

Gross Margin0.00%

Oper. Margin0.00%

Profit Margin0.00%

Debt/Eq0.02

Current Ratio17.50

Quick Ratio17.50

Revenue 5Y-100.00%

Target$15.50

Target Upside315.55%

Target Median$15.50

Target Range14.00 - 17.00

Volume1.08M

Avg Volume1.27M

EPS Surprise0.09

ADN de inversión

Qué tan fuerte luce esta compañía para inversionistas de largo plazo

de 100

Calidad del negocio

Márgenes, ventaja competitiva, retornos

22/100

Fortaleza financiera

Deuda, caja, estabilidad

76/100

Potencial de crecimiento

Ingresos y expansión

20/100

Atractivo del precio

Barata o cara hoy

92/100

Por qué este puntaje▼

Nivel de deuda manejable · 0.02Liquidez saludable · 17.5Tendencia de crecimiento negativaRentabilidad débil

Analyst view

Analyst sentiment and price target

IMRX

Analyst sentiment

Based on 11 analyst votes · 2026-10-20

82/100

Bullish

Hold

Bearish

Precio objetivo

2026-08-14

Bajo

$12.00

Promedio

$14.33

Mediana

$14.00

Alto

$17.00

Resumen de la compañía

IPO: 7/30/2021

Industria: Biotechnology

P/B i: 1.26

Deuda / Patrimonio i: 0.02

Margen operativo: 0.00%

Margen neto: 0.00%

ROE i: -

ROIC: -

Salud financiera

Puntaje15 / 20

Deuda / Patrimonio: 0.02

Ratio corriente: 17.50

Ratio rápido: 17.50

Estado: Good

Transacciones internas

Actividad reciente de ejecutivos e insiders

Gengos Andrew

Transacción: 07/16/2026

COMPRA

Cambio

+650,000

Precio

$4.78

Presentación

07/17/2026

Tipo

COMPRA

Gengos Andrew

Transacción: 07/16/2026

OTRO

Cambio

Precio

Not reported

Presentación

07/16/2026

Tipo

OTRO

Zeskind Benjamin J.

Transacción: 06/23/2026

COMPRA

Cambio

+2,400

Precio

$4.56

Presentación

06/24/2026

Tipo

COMPRA

Insider	Tipo	Cambio	Precio	Transacción	Presentación
Gengos Andrew	COMPRA	+650,000	$4.78	07/16/2026	07/17/2026
Gengos Andrew	OTRO	0	Not reported	07/16/2026	07/16/2026
Zeskind Benjamin J.	COMPRA	+2,400	$4.56	06/23/2026	06/24/2026
Hall Brett Matthew	COMPRA	+6,035	$4.15	06/15/2026	06/16/2026
Feinberg Peter	COMPRA	+33,350	$4.12	06/11/2026	06/11/2026
KEATING LAURIE	COMPRA	+33,350	$4.12	06/11/2026	06/11/2026
CARPENTER ROBERT J	COMPRA	+33,350	$4.12	06/11/2026	06/11/2026
HAUSMAN DIANA	COMPRA	+33,350	$4.12	06/11/2026	06/11/2026
Schall Thomas J.	COMPRA	+33,350	$4.12	06/11/2026	06/11/2026
Neufeld Leah R	COMPRA	+3,628	$4.29	03/13/2026	03/17/2026
Zeskind Benjamin J.	COMPRA	+688,000	$4.91	02/03/2026	02/05/2026
Neufeld Leah R	COMPRA	+140,000	$4.91	02/03/2026	02/05/2026
Morales Mallory	COMPRA	+140,000	$4.91	02/03/2026	02/05/2026
Matushansky Igor	COMPRA	+140,000	$4.91	02/03/2026	02/05/2026
Hall Brett Matthew	COMPRA	+344,000	$4.91	02/03/2026	02/05/2026
Brakewood Harold Eugene	COMPRA	+140,000	$4.91	02/03/2026	02/05/2026
Bookman Michael	COMPRA	+176,000	$4.91	02/03/2026	02/05/2026
Brakewood Harold Eugene	COMPRA	+5,250	$4.76	01/16/2026	01/21/2026
Schall Thomas J.	COMPRA	+21,645	$4.67	01/15/2026	01/20/2026
Hall Brett Matthew	COMPRA	+2,298	$4.57	01/15/2026	01/16/2026

Sobre la compañía

Immuneering Corporation

Immuneering Corporation is a biopharmaceutical company dedicated to developing novel therapeutic candidates in the fields of oncology (cancer) and neuroscience. Leading its clinical development efforts are two key drug candidates: IMM-1-104, a dual-MEK inhibitor intended for the treatment of various cancers, including pancreatic, melanoma, colorectal, and non-small cell lung cancer, specifically those driven by RAS and/or RAF gene mutations. The second is IMM-6-415, which is being developed to treat solid tumors. Beyond these advanced-stage programs, Immuneering's early-stage pipeline includes five oncology initiatives aimed at components of the MAPK or mTOR signaling pathways, along with two neuroscience programs, all currently in the discovery phase. Founded in 2008, Immuneering Corporation is headquartered in Cambridge, Massachusetts. It was formerly a subsidiary of Teva Pharmaceutical Industries Limited.

Fuente - Link

Competidores

ARCT ASMB ENTA FHTX HUMA NAUT PYXS TNYA TRDA ZURA

Tamaño = capitalización · color = línea del gráfico

Rendimiento de peers · 1A

Top performers + empresa seleccionada

Ultimas Noticias

Immuneering to Present at the 41st Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

- Atebimetinib enhances PD-1 checkpoint blockade in preclinical models of RAS mutant tumors - - Findings provide additional mechanistic rationale for upcoming Phase 2 study of atebimetinib in combination with PD-1 blockade in lung cancer patients - NEW YORK, Oct. 02, 2026 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, today announced that a poster will be presented at the 41st Annual Meeting of the Society for Immunotherapy of Cancer (SITC), taking place November 4-8, 2026, in Phoenix, AZ, demonstrating that atebimetinib enhances PD-1 checkpoint blockade in RAS mutant tumor models. These findings support Immuneering's plans to conduct a Phase 2 study of atebimetinib in combination with PD-1 blockade in patients with lung cancer.

GlobeNewsWire

Immuneering Presents Data at 2026 AACR Conference on Pancreatic Cancer Supporting Atebimetinib's Mechanisms Designed to Extend Survival in Pancreatic Cancer

- Stable or increased weight was twice as common among pancreatic cancer patients in the atebimetinib + mGnP study, compared to those in a benchmark study -

GlobeNewsWire

Immuneering to Present at the ESMO Congress 2026

NEW YORK, Sept. 24, 2026 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, today announced that a trial in progress abstract featuring the ongoing Phase 3 MAPKeeper 301 trial of atebimetinib in combination with modified gemcitabine/nab-paclitaxel (mGnP) for the treatment of first-line pancreatic cancer (NCT07562152) has been accepted for poster presentation at the European Society for Medical Oncology (ESMO) Congress 2026, taking place October 23-27, 2026, in Madrid, Spain.

GlobeNewsWire

Squarepoint Ops LLC Has $288,000 Holdings in Immuneering Corporation $IMRX

Squarepoint Ops LLC decreased its position in shares of Immuneering Corporation (NASDAQ: IMRX) by 74.5% in the quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 57,689 shares of the company's stock after selling 168,357 shares during the quarter.

Defense World

Immuneering to Present at the AACR Conference on Pancreatic Cancer, Highlighting Atebimetinib's Dual Mechanism for Extended Survival

- Expands on previously reported findings in which 84% of evaluable first-line PDAC patients treated with atebimetinib + mGnP maintained or gained weight at three months - - New analyses evaluate the overall survival implications of both preserving body mass and reducing tumor volume - NEW YORK, Sept. 10, 2026 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, today announced it will present a poster at the American Association for Cancer Research (AACR) Conference on Pancreatic Cancer: New Frontiers in Biology and Therapeutic Development taking place September 25-28, 2026, in San Diego, CA.

GlobeNewsWire

Sorpresas de ganancias

Período	Estimado	Real	Sorpresa
2026-05-15	-0.3	-0.21	0.09
2026-03-06	-0.31	-0.18	0.13
2025-11-12	-0.37	-0.38	-0.01
2025-08-13	-0.4	-0.4	0
2025-05-05	-0.41	-0.42	-0.01
2025-03-20	-0.42	-0.58	-0.16
2024-11-13	-0.54	-0.49	0.05
2024-08-06	-0.51	-0.47	0.04
2024-05-07	-0.45	-0.49	-0.04
2024-03-01	-0.48	-0.52	-0.04
2023-11-09	-0.51	-0.43	0.08
2023-08-03	-0.54	-0.43	0.11